LH - Laboratory Corp of America Holdings Stock Price, Fair Value and News

201.64USD+0.14 (+0.07%)Market Closed

Market Summary

USD201.64+0.14

Market Closed

0.07%

LH Alerts

3 major insider sales recently.

LH Stock Price

View Fullscreen

LH RSI Chart

LH Valuation

Market Cap

17.0B

Price/Earnings (Trailing)

39.24

Price/Sales (Trailing)

1.38

Price/Free Cashflow

25.46

LH Price/Sales (Trailing)

LH Profitability

Operating Margin

30.24%

Return on Equity

5.44%

Return on Assets

2.62%

Free Cashflow Yield

3.93%

LH Fundamentals

LH Revenue

Revenue (TTM)

12.3B

Rev. Growth (Yr)

4.57%

Rev. Growth (Qtr)

4.72%

LH Earnings

Earnings (TTM)

433.1M

Earnings Growth (Yr)

7.09%

Earnings Growth (Qtr)

236.45%

Breaking Down LH Revenue

Last 7 days

0.2%

Last 30 days

-4.0%

Last 90 days

-9.5%

Trailing 12 Months

5.4%

How does LH drawdown profile look like?

LH Financial Health

Current Ratio

0.88

Debt/Equity

0.38

Debt/Cashflow

0.39

LH Investor Care

Buy Backs (1Y)

18.26%

Diluted EPS (TTM)

5.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	12.3B	0	0	0
2023	13.0B	13.1B	13.3B	12.2B
2022	9.6B	8.7B	7.5B	10.6B
2021	18.1B	19.2B	22.3B	13.1B
2020	10.9B	10.2B	9.5B	16.8B
2019	11.4B	11.4B	11.5B	11.6B
2018	10.7B	11.1B	11.3B	11.3B
2017	9.6B	9.7B	9.9B	10.3B
2016	16.5B	16.7B	16.8B	16.8B
2015	6.4B	7.1B	7.9B	8.7B
2014	10.4B	10.4B	10.5B	10.6B
2013	5.7B	5.7B	5.8B	5.8B
2012	5.6B	5.6B	5.6B	5.7B
2011	5.2B	5.3B	5.5B	5.5B
2010	4.7B	4.8B	4.9B	5.0B
2009	4.6B	4.6B	4.6B	4.7B
2008	0	4.2B	4.4B	4.5B
2007	0	0	0	4.1B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Laboratory Corp of America Holdings

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	anderson kerrii b	sold	-50,024	200	-250	-
Apr 30, 2024	eisenberg glenn a	sold (taxes)	-905,360	201	-4,496	chief financial officer, evp
Apr 30, 2024	anderson kerrii b	sold	-51,033	204	-250	-
Apr 30, 2024	eisenberg glenn a	acquired	-	-	10,229	chief financial officer, evp
Apr 29, 2024	wilkinson peter j	sold	-498,358	204	-2,439	svp, chief accounting officer
Apr 15, 2024	eisenberg glenn a	acquired	-	-	10,229	chief financial officer, evp
Apr 15, 2024	eisenberg glenn a	sold (taxes)	-914,127	203	-4,496	chief financial officer, evp
Apr 01, 2024	schroeder mark s	sold	-1,407,390	217	-6,477	evp, pres diagnostics & coo
Apr 01, 2024	bailey megan d.	acquired	-	-	205	evp, chief strategy officer

Which funds bought or sold LH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Arizona State Retirement System	reduced	-4.00	-427,124	5,101,480	0.04%
May 07, 2024	Illinois Municipal Retirement Fund	unchanged	-	-98,000	2,418,000	0.04%
May 07, 2024	Arnhold LLC	unchanged	-	-48,795	1,207,210	0.13%
May 07, 2024	Moss Adams Wealth Advisors LLC	added	2.95	-2,980	281,815	0.04%
May 07, 2024	WILBANKS SMITH & THOMAS ASSET MANAGEMENT LLC	added	3.09	-106,049	11,477,300	0.32%
May 07, 2024	Chesapeake Wealth Management	unchanged	-	-11,452	283,342	0.10%
May 07, 2024	QRG CAPITAL MANAGEMENT, INC.	added	4.89	91,852	11,351,800	0.14%
May 07, 2024	Mondrian Investment Partners LTD	added	0.94	-3,966,660	129,122,000	1.77%
May 07, 2024	KCM INVESTMENT ADVISORS LLC	reduced	-0.71	-345,130	7,217,260	0.27%
May 07, 2024	Cornerstone Planning Group LLC	unchanged	-	-1,272	9,865	-%

Are Funds Buying or Selling LH?

Are funds buying LH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LH

No. of Funds

LH Alerts

3 major insider sales recently.

Unveiling Laboratory Corp of America Holdings's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.48%	9,745,265	SC 13G/A
Jan 30, 2024	blackrock inc.	12.4%	10,488,875	SC 13G/A
Feb 10, 2023	blackrock inc.	13.0%	11,474,507	SC 13G/A
Feb 09, 2023	vanguard group inc	11.79%	10,450,115	SC 13G/A
Jan 26, 2023	blackrock inc.	13.0%	11,474,507	SC 13G/A
Jan 20, 2023	blackrock inc.	13.0%	11,474,507	SC 13G/A
Mar 09, 2022	blackrock inc.	10.4%	9,706,541	SC 13G/A
Feb 10, 2022	vanguard group inc	11.24%	10,753,065	SC 13G/A
Feb 01, 2022	blackrock inc.	8.6%	8,274,411	SC 13G/A
Feb 10, 2021	vanguard group inc	10.68%	10,405,602	SC 13G/A

Recent SEC filings of Laboratory Corp of America Holdings

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 06, 2024	PX14A6G	PX14A6G
May 03, 2024	144	Notice of Insider Sale Intent
May 02, 2024	144	Notice of Insider Sale Intent
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	144	Notice of Insider Sale Intent
Apr 25, 2024	8-K	Current Report

Peers (Alternatives to Laboratory Corp of America Holdings)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	184.8B	23.7B	2.15%	6.10%	41.98	7.79	-8.94%	-35.91%
A	41.9B	6.7B	-1.12%	12.16%	33.87	6.22	-2.81%	-6.58%
IDXX	40.2B	3.7B	-5.35%	1.62%	46.43	10.8	8.57%	23.94%
DGX	15.1B	9.3B	4.70%	1.87%	17.88	1.63	-3.29%	6.68%
CRL	12.1B	4.1B	-7.72%	25.48%	25.45	2.93	3.86%	-2.39%
MEDP	12.0B	2.0B	-5.25%	88.97%	38.39	6.11	25.57%	21.62%
NTRA	11.5B	1.1B	0.17%	80.36%	-26.55	10.66	31.99%	20.63%
EXAS	11.0B	2.5B	-16.68%	-16.30%	-45.65	4.33	15.21%	53.51%
MID-CAP
NEOG	2.6B	929.2M	-16.06%	-28.54%	1.7K	2.81	28.93%	111.61%
GH	2.3B	563.9M	-0.05%	-22.26%	-4.73	4.03	25.45%	26.76%
SMALL-CAP
CDNA	527.1M	280.3M	6.82%	19.34%	-2.77	1.88	-12.89%	-148.37%
ACRS	86.9M	31.1M	2.52%	-85.27%	-1.13	2.79	0.95%	19.75%
APDN	63.3M	9.0M	832.50%	245.37%	-8.76	7.04	-53.31%	2.21%
AWH	36.8M	9.2M	5.67%	-34.65%	-2.2	4.02	11.85%	44.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Laboratory Corp of America Holdings News

Latest updates

Laboratory Corp of America Holdings Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.7%	3,177	3,033	3,057	3,034	3,038	4,182	2,867	2,923	640	1,071	4,063	3,841	4,162	10,220	947	2,769	2,824	2,953	2,918	2,882	2,835
Cost Of Revenue	3.0%	2,279	2,212	2,206	2,192	2,188	1,829	1,981	1,981	2,667	328	2,677	2,576	2,563	2,585	2,337	2,008	2,096	2,133	2,111	2,057	2,002
Gross Profit	9.2%	897	821	851	842	850	723	886	943	1,233	743	1,386	1,265	1,599	1,905	1,559	761	728	821	817	825	790
S&GA Expenses	-4.6%	508	533	526	506	457	434	453	432	464	282	520	459	430	518	420	396	396	414	402	415	394
Interest Expenses	-3.9%	47.00	49.00	50.00	50.00	51.00	49.00	46.00	42.00	42.00	43.00	42.00	78.00	49.00	48.00	51.00	53.00	55.00	64.00	61.00	59.00	57.00
Income Taxes	250.8%	69.00	20.00	55.00	50.00	64.00	-35.65	38.00	92.00	148	75.00	180	183	252	304	243	65.00	49.00	66.00	66.00	79.00	69.00
Net Income	236.4%	228	-167	183	189	213	76.00	353	359	492	553	587	467	770	938	703	232	-317	227	-317	190	186
Net Income Margin	2.4%	0.04*	0.03*	0.06*	0.07*	0.09*	0.12*	0.23*	0.23*	0.22*	0.18*	0.12*	0.15*	-	-	-	-	-	-	-	-	-
Free Cashflow	-139.7%	-163	412	171	264	27.00	555	291	442	239	586	650	390	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.2%	16,531	16,725	16,886	17,719	20,200	20,155	19,826	20,403	20,728	20,385	20,867	20,417	20,417	20,072	18,740	17,849	17,298	18,046	17,848	17,744	16,971
Current Assets	-8.2%	3,457	3,765	3,954	5,121	4,695	4,625	4,372	5,031	5,230	5,331	6,021	5,694	5,638	5,125	4,086	3,413	2,891	2,981	2,988	2,849	2,885
Cash Equivalents	-81.5%	99.00	537	728	1,931	394	321	410	978	1,234	1,381	2,037	1,963	1,891	1,321	667	557	324	338	361	265	349
Inventory	0.1%	475	475	461	488	481	471	468	436	441	401	411	421	428	423	393	342	254	245	235	220	234
Net PPE	-0.5%	2,898	2,912	2,821	2,762	2,944	2,794	2,885	2,870	2,808	2,815	2,692	2,702	2,697	2,730	2,609	2,628	2,610	2,637	2,463	2,544	2,458
Goodwill	1.2%	6,219	6,143	6,332	6,182	8,116	6,124	8,218	8,114	8,166	5,891	7,907	7,745	7,721	7,752	7,614	7,423	7,389	7,865	7,815	7,844	7,386
Liabilities	-3.2%	8,556	8,835	8,994	8,914	9,839	10,040	9,715	9,982	9,987	10,091	10,321	10,151	10,375	10,614	10,481	10,477	10,260	10,459	10,597	10,580	9,840
Current Liabilities	22.2%	3,942	3,225	2,901	2,183	2,886	3,079	2,522	2,643	2,642	2,783	2,888	2,667	3,369	3,079	3,010	3,034	2,458	2,656	2,555	2,496	2,527
Long Term Debt	-24.8%	3,048	4,055	4,428	5,042	5,052	5,039	5,334	5,360	5,383	5,417	5,417	5,423	4,921	5,419	5,417	5,417	5,790	5,790	6,101	6,135	5,496
LT Debt, Non Current	-24.8%	3,048	4,055	4,428	5,042	5,052	5,039	5,334	5,360	5,383	5,417	5,417	5,423	4,921	5,419	5,417	5,417	5,790	5,790	6,101	6,135	5,496
Shareholder's Equity	1.1%	7,960	7,875	7,873	8,785	10,342	10,097	10,092	10,401	10,721	10,273	10,601	10,322	10,098	9,437	8,239	7,353	7,020	7,644	7,020	7,144	7,111
Retained Earnings	2.1%	8,055	7,888	8,070	8,836	10,730	10,582	10,845	10,898	10,948	10,457	10,787	10,417	10,172	9,479	8,464	7,761	-	7,981	7,677	7,456	7,265
Additional Paid-In Capital	113.5%	82.00	38.00	5.00	94.00	48.00	-	-	-	29.00	-	-	-	67.00	110	81.00	32.00	-	27.00	48.00	91.00	1,401
Shares Outstanding	0.5%	84.00	84.00	85.00	89.00	103	88.00	104	106	112	108	112	113	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	17,300	-	-	-	20,200	-	-	-	24,800	-	-	-	15,200	-	-	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-105.1%	-29.80	580	276	351	121	654	374	573	356	698	767	487	1,158	775	786	371	204	570	456	254	166
Share Based Compensation	17.0%	32.00	27.00	34.00	34.00	33.00	24.00	30.00	26.00	38.00	21.00	59.00	24.00	29.00	27.00	27.00	40.00	18.00	24.00	32.00	27.00	26.00
Cashflow From Investing	-18.9%	-393	-330	-487	-253	-99.70	-273	-563	-242	-573	-254	-407	-90.40	-132	-128	-285	-123	-106	-152	-239	-750	-140
Cashflow From Financing	97.4%	-11.70	-446	-1,097	1,545	-60.60	-372	-452	-479	-17.70	-1,008	-281	-325	-450	-1.00	-396	-16.90	-102	-449	-115	415	-103
Dividend Payments	-	62.00	-	64.00	65.00	64.00	-	65.00	67.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Buy Backs	100.0%	-	-9.00	1,009	-	-	300	400	400	-	1,000	300	300	69.00	-34.25	69.00	-	100	275	100	200	100

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LH Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net restructuring and other special charges	$ 5.0	$ 7.5
Operating Income (Loss)	321.3	329.8
Interest Expense	46.9	50.7
Equity method income, net	0.1	(2.1)
Investment income	2.9	2.2
Other, net	20.0	(6.9)
Earnings before income taxes	297.4	272.3
Provision for income taxes	69.1	63.9
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	228.3	208.4
Net earnings	228.3	213.3
Net Income (Loss) Attributable to Noncontrolling Interest	0.3	0.4
Net Income (Loss) Attributable to Parent	$ 228.0	$ 212.9
Income (Loss) from Continuing Operations, Per Basic Share	$ 2.71	$ 2.35
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share	0	0.06
Basic earnings per common share (in dollars per share)	2.71	2.41
Diluted earnings per common share (in dollars per share)	$ 2.69	$ 2.39
Revenues	$ 3,176.6	$ 3,037.8
Cost of Revenue	2,279.3	2,187.7
Gross Profit	897.3	850.1
Selling, general and administrative expenses	508.4	457.2
Amortization of intangibles and other assets	60.1	53.4
Asset Impairment Charges	2.5	2.2
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 0.0	$ 4.9
Income (Loss) from Continuing Operations, Per Diluted Share	$ 2.69	$ 2.34
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share	$ 0	$ 0.05
Revenues	$ 3,176.6	$ 3,037.8
Cost of Revenue	2,279.3	2,187.7
Gross Profit	897.3	850.1
Selling, general and administrative expenses	508.4	457.2
Amortization of intangibles and other assets	60.1	53.4
Asset Impairment Charges	2.5	2.2
Net restructuring and other special charges	5.0	7.5
Operating Income (Loss)	321.3	329.8
Earnings before income taxes	297.4	272.3
Provision for income taxes	69.1	63.9
Net earnings	228.3	213.3
Less: Net earnings attributable to the noncontrolling interest	(0.3)	(0.4)
Net earnings attributable to Laboratory Corporation of America Holdings	$ 228.0	$ 212.9
Basic earnings per common share (in dollars per share)	$ 2.71	$ 2.41
Diluted earnings per common share (in dollars per share)	$ 2.69	$ 2.39

LH Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Accounts Receivable, after Allowance for Credit Loss, Current	$ 2,083,700,000	$ 1,913,300,000
Unbilled Contracts Receivable	120,400,000	185,400,000
Supplies inventories	475,000,000.0	474,600,000
Prepaid expenses and other	678,100,000	655,300,000
Total current assets	3,456,500,000	3,765,400,000
Property, plant and equipment, net	2,897,800,000	2,911,800,000
Goodwill, net	6,218,900,000	6,142,500,000
Intangible Assets, Net (Excluding Goodwill)	3,394,100,000	3,342,000,000
Joint venture partnerships and equity method investments	17,700,000	26,900,000
Other assets, net	546,000,000.0	536,500,000
Total assets	16,531,000,000	16,725,100,000
Liabilities, Current [Abstract]
Accounts Payable, Current	695,500,000	827,500,000
Accrued Liabilities, Current	649,300,000	804,000,000.0
Deferred Revenue, Current	377,500,000	421,700,000
Operating Lease, Liability, Current	171,300,000	165,800,000
Finance Lease, Liability, Current	6,400,000	6,400,000
Current debt excluding finance lease liability	2,041,500,000	999,800,000
Long-term debt, less current portion	3,941,500,000	3,225,200,000
Long-term Debt, Excluding Current Maturities	3,047,600,000	4,054,700,000
Commitments and contingent liabilities	468,200,000	409,300,000
Operating Lease, Liability, Noncurrent	624,600,000	648,900,000
Finance Lease, Liability, Noncurrent	77,100,000	78,600,000
Deferred income taxes and other tax liabilities	397,200,000	417,900,000
Noncontrolling interest	8,556,200,000	8,834,600,000
Shareholders' equity:
Common stock, 92.8 and 93.5 shares outstanding at March 31, 2013 and December 31, 2012, respectively	15,200,000	15,500,000
Additional paid-in capital	82,000,000.0	38,400,000
Retained earnings	7,700,000	7,700,000
Accumulated other comprehensive income	(8,055,300,000)	(7,888,200,000)
Total liabilities and shareholders' equity	(185,400,000)	(59,300,000)
Stockholders' Equity Attributable to Parent	7,959,600,000	7,875,000,000
Liabilities and Equity	16,531,000,000	16,725,100,000
Net earnings	228,300,000
Cash and cash equivalents	$ 99,300,000	$ 536,800,000

About Laboratory Corp of America Holdings

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

CEO	Mr. Adam H. Schechter
WEBSITE	labcorp.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	60000

Laboratory Corp of America Holdings Frequently Asked Questions

What is the ticker symbol for Laboratory Corp of America Holdings? What does LH stand for in stocks?

LH is the stock ticker symbol of Laboratory Corp of America Holdings. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Laboratory Corp of America Holdings (LH)?

As of Wed May 08 2024, market cap of Laboratory Corp of America Holdings is 17 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LH stock?

You can check LH's fair value in chart for subscribers.

What is the fair value of LH stock?

You can check LH's fair value in chart for subscribers. The fair value of Laboratory Corp of America Holdings is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Laboratory Corp of America Holdings is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Laboratory Corp of America Holdings a good stock to buy?

The fair value guage provides a quick view whether LH is over valued or under valued. Whether Laboratory Corp of America Holdings is cheap or expensive depends on the assumptions which impact Laboratory Corp of America Holdings's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LH.

What is Laboratory Corp of America Holdings's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, LH's PE ratio (Price to Earnings) is 39.24 and Price to Sales (PS) ratio is 1.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Laboratory Corp of America Holdings's stock?

In the past 10 years, Laboratory Corp of America Holdings has provided 0.089 (multiply by 100 for percentage) rate of return.